Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO I Study at the American Society of Clinical Oncology Gastrointestinal Cancers
Omega Therapeutics CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA)